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Abstract
The delivery of bronchodilators with metered-dose inhaler (MDI) in mechanically ventilated
patients has attracted considerable interest in recent years. This is because the use of the
MDI has several advantages over the nebulizer, such as reduced cost, ease of administration,
less personnel time, reliability of dosing and a lower risk of contamination. A spacer device is
fundamental in order to demonstrate the efficacy of the bronchodilatory therapy delivered by
MDI. Provided that the technique of administration is appropriate, MDIs are as effective as
nebulizers, despite a significantly lower dose of bronchodilator given by the MDI.
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COPD = chronic obstructive pulmonary disease; FRC = function residual capacity; MDI = metered-dose inhaler; PEEPi = intrinsic positive end-
expiratory pressure; Pp = plateau pressure; Ptp = transpulmonary pressure; Rint = Rmin = airway resistance; Rmax = total resistance of the respira-
tory system; Vtrap = trapped gas volume above passive functional residual capacity.
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Introduction
Bronchodilator therapy is commonly used in mechanically
ventilated patients [1]. Bronchodilator drugs significantly
decrease airway resistance in patients with obstructive
lung disease, as well as in patients with acute lung injury
[2••,3••,4]. In patients with obstructive lung disease
(chronic obstructive pulmonary disease [COPD] or
asthma), these drugs are part of the standard therapy and
play an important role in patient management [5••,6••]. By
reducing the resistance to airflow, dynamic hyperinflation,
a cardinal feature of the pathophysiology in these patients,
is decreased. This leads to improved synchrony between
the patient and ventilator, less risk of barotrauma and car-
diovascular compromise, and enhancement of respiratory
muscle performance [5••,6••].
In mechanically ventilated patients bronchodilators may be
administered either by the systemic route (ie intra-
venously) or directly to the target site in the endobronchial
tree by inhalation [2••,3••,6••]. Similar to the situation with
ambulatory patients, the inhaled route is preferable during
mechanical ventilation because the drug efficacy is com-
parable or even greater than that of the intravenous drug,
but the side effects are minimized because of the smaller
dose and minimal systemic absorption [2••,3••,6••].
Inhaled bronchodilators in mechanically ventilated patients
may be delivered either by a nebulizer or by a MDI [2••]. It
is generally believed that nebulizers are superior to MDIs
during mechanical ventilation. However, the delivery of
bronchodilators with MDI in mechanically ventilatedCritical Care    Vol 4 No 4 Georgopoulos et al
patients has received considerable interest in recent years
[2••,3••]. This is because the use of MDI has several advan-
tages over the nebulizer, such as reduced cost, ease of
administration, less personnel time, reliability of dosing
and a lower risk of contamination [7–10]. Particularly, in
the present era of limited financial resources, the cost of
therapy is an important issue. Indeed, it has been esti-
mated that substitution of nebulizers with MDIs in a 700-
bed hospital could potentially reduce the cost of aerosol
therapy by US$300000 a year [8]. Moreover, the use of
nebulizers under certain circumstances may lead to
patient/ventilator dyssynchrony [11]. Ineffective efforts
have been identified in patients ventilated on assisted
modes of support whenever the flow rate of continuous in-
line nebulizer exceeded the patient’s inspiratory flow rate
[11]. This may lead to serious episodes of hypoventilation,
which may not be detected by the alarm function because
the bias flow introduced into the system by the continuous
flow is falsely interpreted by the ventilator as representing
minute ventilation. Finally, nebulizers may damage the expi-
ratory transducer of some ventilators, rendering the expira-
tory volume measurement unreliable [12].
Although bronchodilator delivery with MDI in mechanically
ventilated patients has several advantages over nebulizers,
the use of MDIs in this group of patients has not gained
widespread acceptance among intensive care unit physi-
cians. Indeed, bronchodilator delivery with MDI is consid-
ered to be relatively ineffective due to drug deposition in
the ventilator circuit and endotracheal tube [13•]. This
consideration, however, is not supported by recent scien-
tific data. Provided that a proper technique of administra-
tion is used, bronchodilator therapy with MDI is clearly
effective [2••,3••]. In this brief review we present data
regarding the efficacy of MDI in mechanically ventilated
patients, and provide guidelines for proper use of this
mode of bronchodilator therapy.
Respiratory tract deposition of bronchodilator
delivered by MDI
Several factors may affect respiratory tract deposition of
bronchodilator drugs delivered by a MDI during mechani-
cal ventilation. In vitro studies [14•,15–22] have shown
that aerosol deposition is influenced by the ventilator
mode and settings, heat and humidification of inspiratory
gas, density of inhaled gas, size of endotracheal tube, and
method of connecting the MDI in the ventilator circuit.
Bypassing the humidifier, using a large-bore endotracheal
tube and inhalation of less dense gas are associated with
increased aerosol deposition. In particular, heat and
humidification have a great impact on aerosol deposition;
studies [19] have shown that bypassing the humidifier
may increase aerosol deposition to target sites by approxi-
mately 50% (Fig. 1). Endotracheal tubes with less than
6-mm internal diameter decreases significantly the efficacy
of aerosol delivery, which an important issue when bron-
chodilator drugs are administered in children [15].
Synchronization of aerosol delivery with the beginning of
inspiration, large tidal volume, low inspiratory flow and
long duty cycle (TI/TTOT) are also associated with greater
aerosol deposition [14•,19]. Furthermore, active as
opposed to passive mechanical ventilation increases con-
siderably the delivery of bronchodilator drugs [14•,23].
Finally, connecting the MDI in the ventilator circuit using a
spacer device significantly increases the drug deposition
to target sites [20–22]. This is probably among the most
important factors. Indeed studies demonstrated that the
combination of MDI and spacer device resulted in a four-
fold to sixfold greater delivery of bronchodilators com-
pared with MDI actuation into a connector placed directly
at the endotracheal tube or into an in-line device without a
chamber [20–22]. The aerosol delivery to target sites may
approach 30–35% of the nominal dose when a spacer
device is used (Fig. 1) [19]. This is much higher than the
corresponding values obtained with nebulizers (for review
[2••]). Nevertheless, the results of in vitro studies should
be interpreted with caution because bronchodilatation
depends not only on drug dose, but also on several other
factors that are mainly related to the patient.
Figure 1
Drug deposition, expressed as a percentage of nominal dose of
albuterol from a chlorofluorocarbon formulation (CFC) propelled MDI,
in the spacer chamber, the ventilator circuit, the endotracheal tube and
on filters at the bronchi under dry (upper panel) and humidified (lower
panel) conditions during controlled mechanical ventilation. Under dry
conditions 30.4% of the aerosol was deposited at the target sites
(bronchi), versus 16.2% in a humidified circuit. RH, relative humidity; S,
spacer chamber; VC, ventilator circuit; ET, endotracheal tube; B, filters
at the bronchi. From Fink et al [19].http://ccforum.com/content/4/4/227
In vivo drug deposition to the lower respiratory tract may
be estimated by radionuclide methods and by measuring
serum or urine levels of the active drug or its metabolites.
Studies using these methods confirmed the in vitro find-
ings [22,24,25•]. It is of interest to note that Duarte et al
[25•] observed that administration of albuterol with MDI
combined with a spacer device produces peak serum
levels in mechanically ventilated patients that are compa-
rable to those in healthy control individuals, whereas the
area under the concentration time curve was lower in ven-
tilated patients than in control individuals (Fig. 2). It follows
that bronchodilator delivery with MDI and a spacer in
mechanically ventilated patients results in satisfactory
drug deposition in the lower respiratory tract, although its
duration of action might be somewhat decreased.
Assessment of the bronchodilator response
The main outcome variable of bronchodilator therapy is
the resistance to airflow [2••,3••]. Measuring the airflow
resistance in mechanically ventilated patients is not always
an easy task [5••,6••]. In patients with active respiratory
efforts in particular, bedside estimation of resistance as
well as of respiratory mechanics is rather complicated and
imposes unique problems. We briefly review the methods
used to assess bronchodilator response in patients venti-
lated on controlled (ie passive mechanical ventilation) and
assisted modes of ventilatory support.
Patients without respiratory efforts (controlled mechanical
ventilation)
In these patients the bronchodilator response is usually
estimated by measuring inspiratory resistance using the
method of rapid airway occlusion at constant flow inflation
[26•,27]. Briefly, the airways are occluded at end-inspira-
tion, and there is an immediate drop in airway pressure
from a peak to a lower value (P1), followed by a gradual
decay to a plateau pressure (Pp). Airway resistance (Rint
or Rmin) is obtained by dividing the difference between
peak airway pressure and P1 by the preceding constant
inspiratory flow. By dividing the difference between peak
airway pressure and Pp by inspiratory flow, total resis-
tance of the respiratory system (Rmax) is obtained. The
difference between Rmax and Rmin represents two phe-
nomena: time-constant inequalities (pendelluft) and vis-
coelastic behaviour (stress relaxation) [26•,27].
Because reduction in the resistance to airflow decreases
the dynamic hyperinflation, the bronchodilator response
may also be assessed by measuring indices of dynamic
hyperinflation, such as Pp, end-expiratory alveolar pres-
sure (intrinsic positive end-expiratory pressure [PEEPi])
and the trapped gas volume above passive functional
residual capacity (FRC; Vtrap) at the end of expiration
[5••,6••]. PEEPi is measured by occluding the airways at
the end of a tidal expiration and observing the airway pres-
sure [26•,27]. Vtrap is determined by measuring the total
exhaled volume during a period of apnoea for a sufficiently
long period to visually detect expiratory volume change to
cease, thus allowing the patient to reach the passive FRC
[28]. This volume represents the volume above passive
FRC trapped at end-expiration.
Expiratory resistance may better characterize the bron-
chodilator response because it greatly influences dynamic
hyperinflation [5••,6••]. However, expiratory resistance is
difficult to measure in patients with obstructive lung
disease, in whom expiratory flow limitation during tidal
expiration commonly exists [29]. In this case the driving
pressure for flow is not the difference between alveolar
and mouth pressure, but between alveolar pressure and
total pressure head at the choke point, which is very diffi-
cult to measure in humans [30]. Nevertheless, the
decrease in expiratory resistance after bronchodilator
therapy can be indirectly estimated by measuring expira-
tory flow at a given elastic recoil pressure (ie Pp) before
and after bronchodilator delivery [31]. This technique,
however, is cumbersome, time consuming, and necessi-
tates stepwise lung deflation at lung volumes between
end-inspiration and passive FRC. Furthermore, the pause
time may affect Pp independently of volume [32], making
the interpretation of Pp–expiratory flow relationship rather
complex. For these reasons, measurement of expiratory
resistance is rarely used in order to assess the bron-
chodilator response.
Figure 2
Venous serum albuterol, corrected for the number of puffs of albuterol
administered, in mechanically ventilated patients (j) and nonintubated
control individuals (d). Serum levels were similar in both groups
except at baseline and 15 min after drug administration. Note that the
groups had similar patterns of systemic absorption, with the peak level
occurring at 10 min and a rapid decline in serum levels thereafter. Bars
represent standard error. *P<0.05 versus controls. From Duarte et al
[25•].Patients with respiratory efforts (assisted mechanical
ventilation)
In patients ventilated on assisted modes of support, the
bronchodilator response cannot easily be assessed. With
assist volume, static and dynamic airway pressure may
reflect, to a variable extent, respiratory muscle activity, and
thus calculation of resistance using the occlusion tech-
nique is misleading [5••,6••,33•]. Similarly Vtrap can not be
measured in patients with active respiratory efforts. In
these patients the response to bronchodilators may be
estimated indirectly by clinical examination. Reduction in
the number of ineffective efforts and faster response of the
ventilator to patient inspiratory efforts may indicate, among
other causes, a decrease in dynamic hyperinflation due to
a decrease in resistance [5••,6••]. In patients being venti-
lated on pressure support, the decrease in dynamic hyper-
inflation and inspiratory resistance may result in higher
tidal volume [5••,6••].
Measuring the work of breathing is another index that may
by used to assess the bronchodilator response in patients
on assisted modes of ventilation [34]. This, however,
implies insertion of an oesophageal catheter to measure
oesophageal pressure [33•]. This technique is also useful
for measuring respiratory mechanics in patients with active
respiratory efforts. By recording transpulmonary pressure
(Ptp; airway pressure minus oesophageal pressure), flow
and volume over a breath, the weighted average of inspira-
tory and expiratory pulmonary resistance can be estimated
as the ratio of change in Ptp over that of flow between two
points in the breathing cycle in which lung volume is the
same [33•]. Alternatively, inspiratory pulmonary resistance
can be measured as the difference between Ptp at mid-
inspiration and the corresponding pressure on the
Ptp–volume axis (ie relaxation pressure) divided by the
inspiratory flow at that point. The Ptp–volume axis is
obtained by connecting the points of zero flow on the
Ptp–volume curve [33•,35].
In mechanically ventilated patients with active respiratory
efforts, PEEPi can be measured as the amount of change
in oesophageal pressure preceding the initiation of inspi-
ratory flow [33•]. PEEPi measured with this method is valid
provided that expiratory muscles are relaxed. Otherwise,
an additional catheter to record gastric pressure simulta-
neously is needed in order to correct for expiratory muscle
activity [33•]. However, detailed description of the
methods used to measure respiratory mechanics in
patients ventilated on assisted modes is beyond the
scope of the present review.
The techniques described above are not practical and are
rarely used in every day practice. In the busy and crowded
environment of intensive care unit, clinical examination and
assessment of the patient–ventilator interaction remains
the most widely used method to assess the bronchodilator
response in mechanically ventilated patients with active
respiratory efforts.
Efficacy of bronchodilators administered with
MDI in mechanically ventilated patients
Traditionally, nebulizers have been used for bronchodilator
therapy during mechanical ventilation, because bron-
chodilator delivery with a MDI is considered relatively inef-
fective. Manthous et al [13•] reported no benefit from
administration of up to 100 puffs of albuterol (9mg) with
an MDI and elbow adapter in ventilator-supported
patients. Other studies, however, using a spacer device
instead of elbow adapter [36,37,38••,39•,40•,41••], did not
confirm these findings; bronchodilator delivery using an
MDI and a spacer device results in significantly decreased
airflow resistance. Thus, a spacer device is thought to be
fundamental in improving the efficacy of bronchodilator
therapy given by MDI. As a rule, in our unit bronchodilator
drugs are administered using an MDI and a spacer device.
The spacer device we use (Fig. 3) remains in the ventilator
circuit, so that disconnection of the ventilator circuit at
each bronchodilator treatment is avoided.
In patients with COPD, delivery of bronchodilators with an
MDI and a spacer results in approximately 18–25% and
8–15% decreases in Rmin and Rmax, respectively
[36,37,38••,39•,40•,41••]. These decreases are compara-
ble to those observed when bronchodilators are delivered
with a nebulizer, at a fraction of the drug dose [42].
Although expiratory resistance, the main determinant of
dynamic hyperinflation, is usually not measured, indirect
evidence suggests an appreciable decrease in expiratory
resistance also. Indeed, an approximately 20% reduction
in PEEPi has been observed after bronchodilator therapy
[39•,40•,41••], indicating a decrease in dynamic hyperinfla-
tion as a result of a decline in expiratory resistance.
The decrease in total resistance of respiratory system after
bronchodilator delivery with an MDI and a spacer is mainly
due to a decrease in Rmin decrease (ie airway resistance),
whereas the additional resistance due to time-constant
inequalities and/or viscoelastic behaviour remains
unchanged [37,38••,39•,40•,41••,42]. This indicates that
the delivery of bronchodilators with MDI affects the
smooth muscle tone of large airways. On the other hand,
bronchodilators administered using nebulizers seem to
elicit a parenchymal response [42]. Guerin et al [42], in a
recent study in mechanically ventilated COPD patients,
administered a combination of fenoterol–ipratropium
bromide either with a nebulizer or with a MDI, and found
that total resistance of respiratory system, Vtrap and
PEEPi decreased similarly with the two modes of drug
administration. With the nebulizer, the reduction in Rmax
was due to a decrease in the difference between Rmax
and Rmin, whereas with the MDI the decrease was due to
Rmin. The authors attributed these results to the higher
Critical Care    Vol 4 No 4 Georgopoulos et alalveolar deposition of the total drug mass achieved with
the nebulizer, although, as a percentage of the nominal
dose, the deposition was greater with the MDI [42].
The optimal dose of bronchodilators delivered with a MDI
in mechanically ventilated patients is not clearly estab-
lished. Manthaus et al [13•] found, in patients who had
peak pressure–Pp gradient of more than 15 cmH2O, that
five puffs of albuterol (90mg/puff) decreased resistive pres-
sure significantly. The addition of 10 more puffs reduced
the resistive pressure further, but only slightly. Fifteen more
puffs did not result in further improvement. Dhand et al
[38••] showed, in mechanically ventilated patients with
COPD, that the decrease in airway resistance with four
puffs of albuterol was comparable to that observed with
cumulative doses of 28 puffs (Fig. 4). In a recent study
[41••] we demonstrated in COPD patients that two puffs of
salbutamol resulted in significant bronchodilatation that
was comparable to that observed with six puffs.
It seems that, in stable mechanically ventilated patients, two
to six puffs of short acting b2-agonist may achieve maximum
or near maximum bronchodilatation with no side effects.
However, patients with acute bronchospasm (ie status asth-
maticus) may require higher doses. Individual titration of the
dose so as to achieve the best bronchodilatation with
acceptable side effects may be an alternative strategy,
rather than using a standard dose [6••]. In our unit four to six
puffs of short acting b2-agonist is delivered initially, and the
dose is increased according to the response. The optimal
doses of other bronchodilators, such as anticholinergic
agents or long-acting b2-agonists, are not known.
The duration of the bronchodilator response is an important
issue, which surprisingly has not been adequately studied.
In a recent study [43] we observed, in patients with COPD,
that six puffs of salbutamol resulted in significant bronchodi-
latation lasting approximately 3h (Fig. 5). Other studies, pre-
sented so far in abstract form, concluded that the duration
of bronchodilatation in mechanically ventilated patients is
decreased compared with that in ambulatory patients.
These findings are in accordance with those of Duarte et al
[25•], who showed that the relative systemic bioavailability
of albuterol as measured by serum level was reduced in
mechanically ventilated patients. It follows that the dose
interval in mechanically ventilated patients might be shorter
than that in ambulatory patients. As a rule, in our unit we
administer inhaled short-acting bronchodilators every 3–4h.
The technique of administration of bronchodilators in
mechanically ventilated patients using an MDI and a
spacer is an important factor thaty determines the efficacy
of this therapy. Proper timing of drug delivery, relatively
high tidal volumes, low inspiratory flows and application of
end-inspiratory pause (breath-hold) are some of the
factors that have been suggested to enhance drug deliv-
ery to target sites and, thus, bronchodilatation [2••,3••].
However, these suggestions are based, at least as far as
the ventilator settings are concerned, on in vitro studies.
Recently, in a series of studies [39•,40•,41••], we exam-
ined the effects of various ventilator settings on the bron-
chodilatation induced in mechanically ventilated COPD
patients by salbutamol administered using an MDI and a
spacer. These studies demonstrated that neither applica-
tion of 5 s end-inspiratory pause [39•] nor increasing the
tidal volume by 4ml/kg [40•] (strategies that probably
enhanced drug delivery [14•,19]) augmented the bron-
chodilator effect of six puffs of salbutamol. Furthermore,
we showed [41••], at constant tidal volume and inspiratory
time, that changing the inspiratory flow–time profile from
constant (volume controlled) to decelerative flow (pres-
sure controlled) did not have any effect on salbutamol-
http://ccforum.com/content/4/4/227
Figure 3
Schematic representation of the MDI adapted to the spacer device in
the inspiratory limb of the ventilator circuit. Notice that the MDI flume is
directed away from the patient. From Mouloudi et al [40•].
Figure 4
Airway resistance (Rrsmin) in mechanically ventilated patients with
COPD after four, eight and 16 puffs of albuterol (total dose 28 puffs).
The addition of eight and 16 puffs did not cause further
bronchodilatation than that observed with four puffs. **P<0.001 versus
baseline. Bars represent standard error. From Dhand et al [38••].induced bronchodilation, given by MDI and a spacer
[41••]. This was true with both 600 and 200mg salbutamol
(Fig. 6) [41••]. It follows that, in patients with acute exacer-
bation of COPD, significant bronchodilatation can be
achieved both with pressure or volume control, and with
doses of salbutamol as low as 200mg. The similar bron-
chodilatation observed with both high and low dose of the
drug [41••] suggests that the high drug dose used in the
other studies [39•,40•] was not responsible for the failure
of manipulation of ventilator settings to modify the salbuta-
mol-induced bronchodilatation.
The findings of the above studies do not support alter-
ations in ventilator settings when bronchodilator drugs
are administered in mechanically, passively ventilated
patients. For minimizing the importance of manipulation in
ventilator settings, the use of an MDI in mechanically ven-
tilated patients is more appealing because it is easier to
use. In our unit, the strategy for bronchodilator delivery
with an MDI in mechanically ventilated patients is shown
in Table 1.
Conclusion
There is evidence in the literature that the delivery of bron-
chodilators with a MDI and a spacer device in mechani-
cally ventilated patients is effective and results in
bronchodilatation that is comparable to that achieved with
a nebulizer. MDIs have several advantages over nebulizers,
making MDI bronchodilator therapy attractive for use in
mechanically ventilated patients.
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Table 1
Strategy used in our unit for MDI bronchodilator therapy
Step Details
1 Place a spacer device in the inspiratory line of the ventilator
circuit* (see Fig. 3)
2 Shake the MDI vigorously
3 Adapt the MDI to the spacer device
4 Remove the heat and moisture exchanger† (if used)
5 Do not change the ventilator settings‡
6 Actuate MDI to synchronize with the onset of inspiratory flow
7 Repeat actuation after 20–30s until the total dose is
delivered
8 Start with four to six puffs and observe the response
9 Repeat bronchodilator treatment after 3–4h§
*The spacer device remains in the circuit so that disconnection and
manipulation of the ventilator circuit is minimized. †The effect of the
heat–moisture exchanger on the efficiency of bronchodilator therapy
has not been studied; if a humidifier is used it should not be bypassed,
but the drug dose may need to be increased. ‡If the tidal volume is less
that 400ml, an increased dose may be required; this has not been
studied. §A shorter interval may be needed in some patients,
particularly those with status asthmaticus.
Figure 5
Airway resistance (Rint) as a function of time after administration of
600mg salbutamol with MDI and a spacer device in 10 mechanically
ventilated patients with COPD. *P<0.05 versus baseline. From
Mouloudi et al [43].
Figure 6
Relationship between the individual mean bronchodilatory response of
airway resistance (Rint, percentage decrease from baseline) when (a)
200mg (n=8) and (b) 600mg (n=10) salbutamol were given with
volume control (RintVC) and pressure control (RintPC). The mean
bronchodilatory response in each patient was obtained by averaging
the Rint response at 15, 30 and 60 min after salbutamol. For clarity of
presentation, the mean bronchodilatory response was used instead of
data at various time intervals after drug administration. The significant
linear relationships did not change by pooling all data. Note that
significant bronchodilatation was observed both with 200 and 600mg
salbutamol. Note also that the magnitude of bronchodilatation was not
affected by the mode of ventilatory support. The continuous line is the
regression line, and the dashed line represents the line of identity.
From Mouloudi et al [41••].References
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